Moreover, activation of RUNX2 by AKT has more impact and was better investigated in prostate cancer than in breast cancer since prostate cancer mainly causes osteoblastic lesions, and RUNX2 depicts a pro-osteogenic transcription factor. This evidence concerns the gene RUNX2 and Familial prostate cancer.